CZ20014614A3 - Terapeutické činidlo - Google Patents

Terapeutické činidlo Download PDF

Info

Publication number: CZ20014614A3
Authority: CZ; Czechia
Prior art keywords: obesity; formula; compound; lipase inhibitor; methyl
Prior art date: 1999-06-24

Application number

CZ20014614A

Other languages

Czech (cs)

English (en)

Inventor

Alan Martin Birch

David John Heal

Original Assignee

Abbott Gmbh & Co. Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-24

Filing date

2000-06-16

Publication date

2004-02-18

2000-06-16 Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg

2004-02-18 Publication of CZ20014614A3 publication Critical patent/CZ20014614A3/cs

Links

239000000203 mixture Substances 0.000 title description 20
238000009472 formulation Methods 0.000 title description 5
230000001225 therapeutic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 91
229940086609 Lipase inhibitor Drugs 0.000 claims abstract description 47
208000008589 Obesity Diseases 0.000 claims abstract description 42
235000020824 obesity Nutrition 0.000 claims abstract description 42
150000003839 salts Chemical class 0.000 claims abstract description 29
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 22
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 21
229960001243 orlistat Drugs 0.000 claims abstract description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 13
239000001257 hydrogen Substances 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 5
230000008569 process Effects 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 description 22
-1 1- [1- (4-chlorophenyl) cyclobutyl] -3-methylbutyl Chemical group 0.000 description 17
KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 16
125000000217 alkyl group Chemical group 0.000 description 16
229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 description 15
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 14
239000003826 tablet Substances 0.000 description 14
229960004425 sibutramine Drugs 0.000 description 13
229910052717 sulfur Inorganic materials 0.000 description 11
230000004580 weight loss Effects 0.000 description 11
229910052760 oxygen Inorganic materials 0.000 description 10
239000002775 capsule Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000001301 oxygen Substances 0.000 description 8
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
150000002431 hydrogen Chemical class 0.000 description 6
125000004434 sulfur atom Chemical group 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229940127470 Lipase Inhibitors Drugs 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000003710 aryl alkyl group Chemical group 0.000 description 4
230000037396 body weight Effects 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
235000021235 fat-rich diet Nutrition 0.000 description 4
230000037406 food intake Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000000829 suppository Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
239000000725 suspension Substances 0.000 description 3
NEBHNFJAFFHYGN-BYPYZUCNSA-N (2s)-2-carbamoyl-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(N)=O)C(O)=O NEBHNFJAFFHYGN-BYPYZUCNSA-N 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000002705 Glucose Intolerance Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
108050006759 Pancreatic lipases Proteins 0.000 description 2
102000019280 Pancreatic lipases Human genes 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
125000001118 alkylidene group Chemical group 0.000 description 2
125000004659 aryl alkyl thio group Chemical group 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
125000004387 flavanoid group Chemical group 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000001030 gas--liquid chromatography Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
229940116369 pancreatic lipase Drugs 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
201000009104 prediabetes syndrome Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000000758 substrate Substances 0.000 description 2
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
HFBHOAHFRNLZGN-LURJTMIESA-N (2s)-2-formamido-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC=O HFBHOAHFRNLZGN-LURJTMIESA-N 0.000 description 1
FKUNIADJSAJLGB-FWEHEUNISA-N (2s,3s,5s)-5-[(2s)-2-formamido-4-methylpentanoyl]oxy-2-hexyl-3-hydroxyhexadecanoic acid Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@H](O)[C@H](CCCCCC)C(O)=O FKUNIADJSAJLGB-FWEHEUNISA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
MCANQXNXHKXBML-UHFFFAOYSA-N 2-carbamoylpentanoic acid Chemical compound CCCC(C(N)=O)C(O)=O MCANQXNXHKXBML-UHFFFAOYSA-N 0.000 description 1
MENAYYMPBRSAAE-AWEZNQCLSA-N 3-[[5-[[(2s)-1-carboxy-3-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]benzoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C(O)=O)=C1 MENAYYMPBRSAAE-AWEZNQCLSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
208000022540 Consciousness disease Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
IVWAWEHNQKOTOU-XEHUPPEPSA-N [(2r)-2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl] adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1([14C](=O)OC[C@@H](COC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC)C3 IVWAWEHNQKOTOU-XEHUPPEPSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical class O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
229950002397 cetilistat Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
102000005311 colipase Human genes 0.000 description 1
108020002632 colipase Proteins 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
231100000867 compulsive behavior Toxicity 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
IERCWZWOKCAFTO-INIZCTEOSA-N dodecyl (2s)-2-carbamoyl-3-methylbutanoate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H](C(C)C)C(N)=O IERCWZWOKCAFTO-INIZCTEOSA-N 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
235000021374 legumes Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940040461 lipase Drugs 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000966 norepinephrine reuptake Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000003380 propellant Substances 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229960003466 sibutramine hydrochloride Drugs 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019710 soybean protein Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
150000003648 triterpenes Chemical class 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000011680 zucker rat Methods 0.000 description 1
229930007845 β-thujaplicin Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Child & Adolescent Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CZ20014614A 1999-06-24 2000-06-16 Terapeutické činidlo CZ20014614A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9914742.3A GB9914742D0 (en)	1999-06-24	1999-06-24	Therapeutic agents

Publications (1)

Publication Number	Publication Date
CZ20014614A3 true CZ20014614A3 (cs)	2004-02-18

Family

ID=10855953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20014614A CZ20014614A3 (cs)	1999-06-24	2000-06-16	Terapeutické činidlo

Country Status (20)

Country	Link
EP (1)	EP1189638A2 (no)
JP (1)	JP2003503344A (no)
KR (1)	KR20020012293A (no)
CN (1)	CN1365287A (no)
AU (1)	AU5815100A (no)
BG (1)	BG106209A (no)
BR (1)	BR0011884A (no)
CA (1)	CA2376213A1 (no)
CZ (1)	CZ20014614A3 (no)
GB (1)	GB9914742D0 (no)
HK (1)	HK1050476A1 (no)
HU (1)	HUP0201880A3 (no)
IL (1)	IL147078A0 (no)
MX (1)	MXPA01013023A (no)
NO (1)	NO20016301L (no)
PL (1)	PL352387A1 (no)
SK (1)	SK18822001A3 (no)
TR (1)	TR200103704T2 (no)
WO (1)	WO2001000187A2 (no)
ZA (1)	ZA200110046B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399826B1 (en) *	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US7089666B2 (en) *	2003-06-06	2006-08-15	The Regents Of The University Of California	Microfabricated vertical comb actuator using plastic deformation
MX2009002781A (es)	2006-09-15	2009-03-30	Reviva Pharmaceuticals Inc	Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
US8604244B2 (en)	2010-07-02	2013-12-10	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN101890017A (zh) *	2009-05-22	2010-11-24	北京奥萨医药研究中心有限公司	含有西布曲明和他汀类降脂药物的药物组合物及其用途
ES2726807T3 (es)	2011-12-30	2019-10-09	Reviva Pharmaceuticals Inc	Composiciones, síntesis y métodos de uso de derivados de 1-[1-fenil-ciclobutil]isobutilamina

1999
- 1999-06-24 GB GBGB9914742.3A patent/GB9914742D0/en not_active Ceased
2000
- 2000-06-16 JP JP2001505897A patent/JP2003503344A/ja active Pending
- 2000-06-16 BR BR0011884-2A patent/BR0011884A/pt not_active IP Right Cessation
- 2000-06-16 CN CN00810544A patent/CN1365287A/zh active Pending
- 2000-06-16 EP EP00943819A patent/EP1189638A2/en not_active Withdrawn
- 2000-06-16 CA CA002376213A patent/CA2376213A1/en not_active Abandoned
- 2000-06-16 SK SK1882-2001A patent/SK18822001A3/sk unknown
- 2000-06-16 HK HK03101311.7A patent/HK1050476A1/zh unknown
- 2000-06-16 WO PCT/EP2000/005544 patent/WO2001000187A2/en not_active Ceased
- 2000-06-16 TR TR2001/03704T patent/TR200103704T2/xx unknown
- 2000-06-16 PL PL00352387A patent/PL352387A1/xx unknown
- 2000-06-16 MX MXPA01013023A patent/MXPA01013023A/es unknown
- 2000-06-16 HU HU0201880A patent/HUP0201880A3/hu unknown
- 2000-06-16 CZ CZ20014614A patent/CZ20014614A3/cs unknown
- 2000-06-16 AU AU58151/00A patent/AU5815100A/en not_active Abandoned
- 2000-06-16 IL IL14707800A patent/IL147078A0/xx unknown
- 2000-06-16 KR KR1020017016577A patent/KR20020012293A/ko not_active Ceased
2001
- 2001-12-06 ZA ZA200110046A patent/ZA200110046B/xx unknown
- 2001-12-11 BG BG06209A patent/BG106209A/xx unknown
- 2001-12-21 NO NO20016301A patent/NO20016301L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2001000187A3 (en)	2001-11-15
ZA200110046B (en)	2003-03-06
HUP0201880A3 (en)	2003-03-28
BG106209A (en)	2002-09-30
CN1365287A (zh)	2002-08-21
IL147078A0 (en)	2002-08-14
BR0011884A (pt)	2003-08-12
NO20016301D0 (no)	2001-12-21
NO20016301L (no)	2001-12-21
GB9914742D0 (en)	1999-08-25
EP1189638A2 (en)	2002-03-27
AU5815100A (en)	2001-01-31
SK18822001A3 (sk)	2003-04-01
CA2376213A1 (en)	2001-01-04
HK1050476A1 (zh)	2003-06-27
MXPA01013023A (es)	2003-08-01
HUP0201880A2 (hu)	2002-12-28
KR20020012293A (ko)	2002-02-15
PL352387A1 (en)	2003-08-25
WO2001000187A2 (en)	2001-01-04
JP2003503344A (ja)	2003-01-28
TR200103704T2 (tr)	2002-05-21

Publication	Publication Date	Title
RU2197959C2 (ru)	2003-02-10	Применение аналогов сибутрамина для снижения уровней липидов
WO2001062341A2 (en)	2001-08-30	Combination product for the treatment of obesity
US6403641B2 (en)	2002-06-11	Therapeutic agents
JP2010506845A (ja)	2010-03-04	フェニルアルキルアミノカルバメート組成物
RU2229289C2 (ru)	2004-05-27	Фармацевтическая композиция, содержащая сибутрамин и орлистат
CZ20014614A3 (cs)	2004-02-18	Terapeutické činidlo
US6232347B1 (en)	2001-05-15	Treatment of osteoarthritis
US3961073A (en)	1976-06-01	Antidepressant
US6403650B1 (en)	2002-06-11	Treatment of pulmonary hypertension
KR20020038567A (ko)	2002-05-23	골관절염의 치료방법
RU2234917C2 (ru)	2004-08-27	Терапевтические средства
MXPA00006201A (en)	2001-06-26	Pharmaceutical composition containing sibutramine and orlistat
WO2000056316A1 (en)	2000-09-28	Treatment of gallstones
WO2000056308A1 (en)	2000-09-28	Prevention of cardiovascular disease
CZ20013282A3 (cs)	2002-07-17	Farmaceutická kompozice